Compare Johnson & Johnson (JNJ) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Teradyne, Inc. — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while Teradyne, Inc. trades at $353.39 (market cap $52.25B). The key difference: Johnson & Johnson is far larger — about 11.5× Teradyne, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | TER | |
|---|---|---|
Market Cap | $598.96B | $52.25B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $483.84 |
52-Week Low | $164.36 | $90.15 |
Enterprise Value | $631.90B | $52.08B |
Dividend Yield | 2.15% | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Teradyne (TER) trades at $334.23, up 3.68% on the day, with strong recent earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but benefits from high profitability margins (net income margin 22.55%) and consistent revenue growth, projected to reach $3.8B in 2026. Analysts maintain a bullish consensus with a $453.60 price target, citing AI infrastructure expansion and recent product launches as key catalysts.
Outlook remains positive given TER's strategic positioning in AI and semiconductor testing, though elevated valuation ratios (P/E 59.81) and technical bearishness pose near-term risks. Investment opportunity hinges on execution in high-growth AI segments, while risks include market volatility and competitive pressures in the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
